NCT06614725 - A Study in India on the Immune Response and Safety of a Respiratory Syncytial Virus (RSV) Older Adults (OA) Vaccine When Given to Older Adults 60 Years of Age and Above and Adults 50-59 Years of Age at Increased Risk (AIR) of Respiratory Syncytial Virus Lower Respiratory Tract Disease (RSV-LRTD) | Biotech Hunter

Enrollment

751

Participants

Timeline

Start Date

October 1, 2024

Primary Completion Date

June 3, 2025

Study Completion Date

November 24, 2025

Conditions

Respiratory Syncytial Virus Infections

Interventions

BIOLOGICAL

RSVPreF3 OA investigational vaccine

1 dose of RSVPreF3 OA investigational vaccine administered intramuscularly on Day 1 to participants in OA-RSV and Adults-AIR-RSV groups.

COMBINATION_PRODUCT

Placebo

1 dose of placebo (saline solution) administered intramuscularly on Day 1 to participants in OA-Placebo and Adults-AIR-Placebo groups.

Trial Locations (14)

GSK Investigational Site, Delhi

GSK Investigational Site, Aligarh

GSK Investigational Site, Kanpur

GSK Investigational Site, Ahmedabad

GSK Investigational Site, Ahmedabad

GSK Investigational Site, Pune-411 043

GSK Investigational Site, Vadu Budruk Pune

GSK Investigational Site, Bangalore

GSK Investigational Site, Belagavi

GSK Investigational Site, Kelambākkam

GSK Investigational Site, Kochi

GSK Investigational Site, Kolkata

GSK Investigational Site, Darjeeling

GSK Investigational Site, Raipur